Real-World Evidence for Control of Chronic Migraine (CM) in Patients Meeting American Headache Society (AHS) Criteria Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to OnabotulinumtoxinA Treatment

被引：0
|
作者：
Blumenfeld, Andrew M. [1 ]
Frishberg, Benjamin M. [1 ]
Schim, Jack D. [1 ]
Iannone, Ashley [2 ]
Yedigarova, Larisa [3 ]
Adams, Aubrey Manack [3 ]
机构：
[1] Headache Ctr Southern California, Neurol Ctr, Irvine, CA USA
[2] ICON Plc, Dublin, Ireland
[3] AbbVie Co, Allergan, Lake Bluff, IL USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1430
引用
收藏
页数：4
相关论文
共 40 条
  • [1] Real-world evidence for control of chronic migraine in patients meeting American Headache Society criteria who received calcitonin gene-related peptide monoclonal antibody therapy added to OnabotulinumtoxinA
    Blumenfeld, A. M.
    Frishberg, B. M.
    Schim, J. D.
    Hughes, O.
    Yedigarova, L.
    Adams, Manack A.
    HEADACHE, 2021, 61 : 140 - 141
  • [2] Real-world evidence for control of patients with chronic migraine who received calcitonin gene-related peptide monoclonal antibody therapy added to OnabotulinumtoxinA treatment
    Blumenfeld, A. M.
    Frishberg, B. M.
    Schim, J. D.
    Hughes, O.
    Adams, Manack A.
    HEADACHE, 2021, 61 : 106 - 107
  • [3] Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
    Blumenfeld, A. M.
    Frishberg, B. M.
    Schim, J. D.
    Hughes, O.
    Adams, A. Manack
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 104 - 105
  • [4] Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
    Blumenfeld, A. M.
    Frishberg, B. M.
    Schim, J. D.
    Hughes, O.
    Adams, A. Manack
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 155 - 155
  • [5] Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Yedigarova, Larisa
    Adams, Aubrey Manack
    NEUROLOGY, 2021, 96 (15)
  • [6] REAL-WORLD EVIDENCE FOR CONTROL OF PATIENTS WITH CHRONIC MIGRAINE WHO RECEIVED CGRP MONOCLONAL ANTIBODY THERAPY ADDED TO ONABOTULINUMTOXINA TREATMENT
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Adams, Aubrey Manack
    CEPHALALGIA, 2020, 40 : 96 - 97
  • [7] Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (10): : 1119 - 1128
  • [8] Real-world Adherence to Subsequent Prophylactic Therapy Among Chronic Migraine (CM) Patients Initially Treated With a Calcitonin Gene-related Peptide Monoclonal Antibody (CGRP mAb)
    Gusovsky, Amanda
    Dong, Yanan
    Zhao, Changgeng
    Park, Tae Jin
    Shah, Darshini
    NEUROLOGY, 2023, 100 (17)
  • [9] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine
    Mechtler, L. L.
    Saikali, N. P.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    HEADACHE, 2021, 61 : 176 - 177
  • [10] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 48 - 49
1234